Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 11:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1609–1632 of 10,564 matching trials from the live ClinicalTrials.gov search.
Conditions
Depression, Bipolar
Interventions
Not listed
Lead sponsor
University of Cincinnati
Other
Eligibility
12 Years to 35 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Autoimmune Pulmonary Alveolar Proteinosis
Interventions
Sargramostim
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Los Altos, California • Cincinnati, Ohio
Conditions
Oral Herpes Simplex
Interventions
Matching Placebo, BTL-TML-HSV
Drug
Lead sponsor
Beech Tree Labs, Inc.
Industry
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
3
States / cities
St. Petersburg, Florida • Cincinnati, Ohio • Mt. Pleasant, South Carolina
Completed Not applicable Interventional Results available

Response Inhibition in Tourette Syndrome

NCT03628703
Conditions
Tourette Syndrome
Interventions
Repetitive TMS
Device
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
10 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Indacaterol 150 μg, Placebo to indacaterol
Drug
Lead sponsor
Novartis
Industry
Eligibility
40 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
118
States / cities
Anniston, Alabama • Birmingham, Alabama • Jasper, Alabama + 105 more
Conditions
Chronic Total Occlusion of Artery of the Extremities
Interventions
1. CROSSER System
Device
Lead sponsor
C. R. Bard
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
8
States / cities
Washington D.C., District of Columbia • Des Moines, Iowa • Detroit, Michigan + 5 more
Conditions
Primary Mediastinal Large B-Cell Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Echocardiography Test, Etoposide Phosphate, Filgrastim, Lumbar Puncture, Nivolumab, Pegfilgrastim, Positron Emission Tomography, Prednisolone, Prednisone, Radiation Therapy, Rituximab, Rituximab and Hyaluronidase Human, Vincristine Sulfate
Procedure · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
215
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 162 more
Conditions
Tourettes Disorder, Tourette Disorder
Interventions
ecopipam HCl ~2mg/kg/day
Drug
Lead sponsor
Emalex Biosciences Inc.
Industry
Eligibility
6 Years to 50 Years
U.S. locations
26
States / cities
Glendale, California • San Rafael, California • New Haven, Connecticut + 18 more
Conditions
Prostate Cancer
Interventions
Vinflunine
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older · Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
12
States / cities
Fort Myers, Florida • Jacksonville, Florida • Orlando, Florida + 8 more
Conditions
Ductal Breast Carcinoma, Invasive Breast Carcinoma, Lobular Breast Carcinoma, Medullary Breast Carcinoma, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Tubular Breast Carcinoma
Interventions
Radiation Therapy, Questionnaire Administration, Quality-of-Life Assessment, Laboratory Biomarker Analysis, Hypofractionated Radiation Therapy
Radiation · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
898 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2035
U.S. locations
846
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 544 more
Conditions
Dry Eye Disease (DED)
Interventions
011516X (New Artificial Tear Formulation), Systane Ultra Multidose, REFRESH PLUS®
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
26
States / cities
Azusa, California • Glendale, California • Newport Beach, California + 22 more
Conditions
Chronic Spontaneous Urticaria
Interventions
CDX-0159, Normal Saline
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
13
States / cities
Birmingham, Alabama • Gilbert, Arizona • Sarasota, Florida + 10 more
Conditions
Crohn's Disease
Interventions
Risankizumab, Lutikizumab, Trosunilimab, ABBV-8736
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
64
States / cities
Dothan, Alabama • Mobile, Alabama • Coronado, California + 56 more
Completed Not applicable Interventional Results available

Diabetes Journey: An Adolescent Adherence Barriers Intervention

NCT04404556
Conditions
Type 1 Diabetes, Adherence, Patient
Interventions
Diabetes Journey, Enhanced Standard of Care
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
13 Years to 17 Years
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Gainesville, Florida • Cincinnati, Ohio
Conditions
Breast Cancer
Interventions
Photon, Proton
Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
21 Years and older
Enrollment
1,238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2036
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 33 more
Active, not recruiting Phase 3 Interventional Results available

The Budesonide in Babies (BiB) Trial

NCT04545866
Conditions
Bronchopulmonary Dysplasia (BPD), Respiratory Distress Syndrome, Prematurity; Extreme, Neonatal
Interventions
budesonide (Pulmicort nebulizing suspension)., surfactant (poractant alfa;Curosurf)
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 48 Hours
Enrollment
642 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
19
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 15 more
Conditions
Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ
Interventions
Intismeran autogene, BCG
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
20
States / cities
Bakersfield, California • Los Alamitos, California • Los Angeles, California + 15 more
Completed Phase 2Phase 3 Interventional Results available

Double Blind Trial of Duloxetine in Chronic Fatigue Syndrome

NCT00375973
Conditions
Fatigue Syndrome, Chronic
Interventions
Duloxetine, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Systemic Juvenile Idiopathic Arthritis
Interventions
Canakinumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 19 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
15
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 10 more
Conditions
Sickle Cell Disease
Interventions
Zileuton
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Atopic Dermatitis
Interventions
Tralokinumab
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
12 Years and older
Enrollment
1,672 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
95
States / cities
Birmingham, Alabama • Mobile, Alabama • Fort Smith, Arkansas + 78 more
Conditions
Migraine
Interventions
Erenumab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
31
States / cities
Long Beach, California • Los Angeles, California • Basalt, Colorado + 28 more
Conditions
Primary Prevention of Atherosclerotic Cardiovascular Disease
Interventions
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, Placebo in 1.5ml
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 79 Years
Enrollment
14,012 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
241
States / cities
Birmingham, Alabama • Fairhope, Alabama • Foley, Alabama + 187 more
Conditions
Multiple Sclerosis
Interventions
Frexalimab, Placebo, MRI contrast-enhancing agents
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 60 Years
Enrollment
943 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
79
States / cities
Homewood, Alabama • Scottsdale, Arizona • Berkeley, California + 68 more